Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 288 articles:
HTML format
Text format



Single Articles


    June 2018
  1. LIU Y, Ye L, Lin F, Gomaa Y, et al
    Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.
    J Infect Dis. 2018 Jun 8. pii: 5034941. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  2. SWANSTROM JA, Henein S, Plante JA, Yount BL, et al
    Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
    J Infect Dis. 2018;217:1932-1941.
    PubMed     Text format     Abstract available


  3. KAINULAINEN MH, Spengler JR, Welch SR, Coleman-McCray JD, et al
    Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    J Infect Dis. 2018;217:1957-1966.
    PubMed     Text format     Abstract available


  4. PERCIANI CT, Sekhon M, Hundal S, Farah B, et al
    Live-attenuated Zoster Vaccine Boosts VZV-specific Humoral Responses Systemically and at the Cervico-vaginal Mucosa of Kenyan VZV-seropositive Women.
    J Infect Dis. 2018 May 25. pii: 5003463. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. CHAKRABORTY S, Randall A, Vickers TJ, Molina D, et al
    Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development.
    J Infect Dis. 2018 May 24. pii: 5003007. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. PAMNANI SJ, Sudenga SL, Rollison DE, Ingles DJ, et al
    Recurrence of Genital Infections with Nine HPV Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) among Men in the HPV Infection in Men (HIM) Study.
    J Infect Dis. 2018 May 24. pii: 5002064. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. BERNSTEIN DI
    Rotavirus Vaccines: Mind Your Ps and Gs.
    J Infect Dis. 2018 May 22. pii: 5001445. doi: 10.1093.
    PubMed     Text format    


  8. ROCZO-FARKAS S, Kirkwood CD, Cowley D, Barnes GL, et al
    The Impact of Rotavirus Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of Australian Surveillance Data.
    J Infect Dis. 2018 May 22. pii: 5001444. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. KABINEH AK, Carr W, Motevalli M, Legardy-Williams J, et al
    Operationalizing International Regulatory Standards in a Limited-Resource Setting During an Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Experience.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  10. CARTER RJ, Senesi RGB, Dawson P, Gassama I, et al
    Participant Retention in a Randomized Clinical Trial in an Outbreak Setting: Lessons From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  11. CONTEH MA, Goldstein ST, Wurie HR, Gidudu J, et al
    Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  12. JARRETT OD, Seward JF, Fombah AE, Lindblad R, et al
    Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  13. SAMAI M, Seward JF, Goldstein ST, Mahon BE, et al
    The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVG-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  14. SCHUCHAT A, Seward JF, Goldstein ST, Mahon BE, et al
    Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format    


  15. CARTER RJ, Idriss A, Widdowson MA, Samai M, et al
    Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  16. FOMBAH AE, Goldstein ST, Jarrett OD, Jalloh MI, et al
    Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  17. EDEM-HOTAH J, McDonald W, Abu PM, Luman ET, et al
    Utilizing Nurses to Staff an Ebola Vaccine Clinical Trial in Sierra Leone during the Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  18. JUSU MO, Glauser G, Seward JF, Bawoh M, et al
    Rapid Establishment of a Cold Chain Capacity of -60 degrees C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  19. GARLAND SM, Pitisuttithum P, Ngan HYS, Cho CH, et al
    Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    J Infect Dis. 2018 May 15. pii: 4996119. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. FARMAKI PF, Chini MC, Mangafas NM, Tzanoudaki MT, et al
    Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    J Infect Dis. 2018 May 2. pii: 4990938. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  21. CARROLL TD, Jegaskanda S, Matzinger SR, Fritts L, et al
    A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus macaques from uncontrolled virus replication after heterosubtypic influenza A virus challenge.
    J Infect Dis. 2018 Apr 26. pii: 4986227. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. JOYCE JC, Carroll TD, Collins ML, Chen MH, et al
    A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
    J Infect Dis. 2018 Apr 26. pii: 4986788. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. LIN KY, Hsieh SM, Sheng WH, Lo YC, et al
    Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan.
    J Infect Dis. 2018 Apr 16. pii: 4972613. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. BADEN LR, Walsh SR, Seaman MS, Cohen YZ, et al
    First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    J Infect Dis. 2018 Apr 13. pii: 4969772. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. HAIDARA FC, Tapia MD, Sow SO, Doumbia M, et al
    Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants.
    J Infect Dis. 2018 Apr 12. pii: 4969416. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. ZIMMERMANN P, Finn A, Curtis N
    Does BCG Vaccination Protect Against Non-Tuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.
    J Infect Dis. 2018 Apr 7. pii: 4964710. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  27. LANGLEY JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, et al
    A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
    J Infect Dis. 2018 Mar 30. pii: 4956800. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. MANNING JE, Morens DM, Kamhawi S, Valenzuela JG, et al
    Mosquito saliva: the hope for a universal arbovirus vaccine?
    J Infect Dis. 2018 Mar 29. pii: 4956143. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. GUO Q, Chan JF, Poon VK, Wu S, et al
    Immunization with a Novel Human type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
    J Infect Dis. 2018 Mar 29. pii: 4956202. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. FENG G, Boyle MJ, Cross N, Chan JA, et al
    Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains.
    J Infect Dis. 2018 Mar 23. pii: 4952401. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. PATEL EU, Grabowski MK, Eisenberg AL, Packman ZR, et al
    Increases in Human Papillomavirus Vaccination Among Adolescent and Young Adult Males in the United States, 2011-2016.
    J Infect Dis. 2018 Mar 23. pii: 4951824. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. ANGRISANO F, Blagborough AM
    Understanding human-derived antibodies generated by polymorphic malaria vaccine against merozoite surface protein 2.
    J Infect Dis. 2018 Mar 23. pii: 4952403. doi: 10.1093.
    PubMed     Text format    


  33. SCHLEISS MR
    Searching for a Serological Correlate of Protection for a CMV Vaccine.
    J Infect Dis. 2018 Mar 8. pii: 4924674. doi: 10.1093.
    PubMed     Text format    


  34. BARANIAK I, Kropff B, McLean GR, Pichon S, et al
    Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine with MF59: Anti-AD2 Levels Correlate with Protection from Viremia.
    J Infect Dis. 2018 Mar 8. pii: 4924673. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. ROGAWSKI ET, Platts-Mills JA, Colgate ER, Haque R, et al
    Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study.
    J Infect Dis. 2018;217:861-868.
    PubMed     Text format     Abstract available


  36. BUCHHOLZ UJ, Cunningham CK, Muresan P, Gnanashanmugam D, et al
    Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    J Infect Dis. 2018 Mar 2. pii: 4917539. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. POLACK FP
    Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus.
    J Infect Dis. 2018 Mar 2. pii: 4917537. doi: 10.1093.
    PubMed     Text format    


  38. MCFARLAND EJ, Karron RA, Muresan P, Cunningham CK, et al
    Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.
    J Infect Dis. 2018 Mar 2. pii: 4917538. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  39. ERBELDING EJ, Post D, Stemmy E, Roberts PC, et al
    A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
    J Infect Dis. 2018 Feb 28. pii: 4904047. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. CUNNINGHAM AL, Heineman TC, Lal H, Godeaux O, et al
    Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged >/=50 Years.
    J Infect Dis. 2018 Feb 26. pii: 4911103. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. YOUNG-XU Y, Van Aalst R, Mahmud SM, Rothman KJ, et al
    Relative Vaccine Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among Veterans Health Administration Patients.
    J Infect Dis. 2018 Feb 14. pii: 4858294. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. KOJIC EM, Conley L, Bush T, Cu-Uvin S, et al
    Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types covered by Current HPV Vaccines among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study
    J Infect Dis. 2018 Feb 14. pii: 4857222. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. LO NC, Gupta R, Stanaway JD, Garrett DO, et al
    Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    J Infect Dis. 2018 Feb 12. pii: 4851280. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. ZENKLUSEN I, Jongo S, Abdulla S, Ramadhani K, et al
    Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies.
    J Infect Dis. 2018 Feb 8. pii: 4845622. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. MACHALEK DA, Garland SM, Brotherton JML, Bateson D, et al
    Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination.
    J Infect Dis. 2018 Feb 7. pii: 4841780. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. FREYNE B, Donath S, Germano S, Gardiner K, et al
    Neonatal BCG vaccination influences cytokine responses to Toll-like receptor ligands and heterologous antigens.
    J Infect Dis. 2018 Feb 3. pii: 4837044. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. DONKEN R, King AJ, Bogaards JA, Woestenberg PJ, et al
    High effectiveness of the bivalent HPV vaccine up to six years post-vaccination against incident and persistent HPV infections in young Dutch females.
    J Infect Dis. 2018 Feb 2. pii: 4835373. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. LEVIN MJ, Cai GY, Lee KS, Rouphael NG, et al
    Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835758. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. POLLOCK KGJ
    Sustained cross-protection of the bivalent HPV vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835375. doi: 10.1093.
    PubMed     Text format    


  50. BERAN J, Lickliter JD, Schwarz TF, Johnson C, et al
    Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in non-pregnant women: results from two phase II trials.
    J Infect Dis. 2018 Feb 1. pii: 4833521. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. SHANG L, Smith AJ, Duan L, Perkey KE, et al
    Vaccine-associated maintenance of epithelial integrity correlated with protection against virus entry.
    J Infect Dis. 2018 Feb 1. pii: 4833184. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  52. LEE B, Dickson DM, deCamp AC, Colgate ER, et al
    Histoblood Group Antigen Phenotype Determines Susceptibility to Genotype-specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy.
    J Infect Dis. 2018 Jan 30. pii: 4829672. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. MALHOTRA I, LaBeaud AD, Morris N, McKibben M, et al
    Cord Blood Anti-Parasite IL-10 as Risk Marker for Compromised Vaccine Immunogenicity in Early Childhood.
    J Infect Dis. 2018 Jan 30. pii: 4829506. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. JUNG J, Ko SJ, Oh HS, Moon SM, et al
    Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome.
    J Infect Dis. 2018 Jan 24. pii: 4823438. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. CHENG AC, Subbarao K
    Epidemiological Data on the Effectiveness of Influenza Vaccine-Another Piece of the Puzzle.
    J Infect Dis. 2018 Jan 18. pii: 4816917. doi: 10.1093.
    PubMed     Text format    


  56. FLANNERY B, Smith C, Garten RJ, Levine MZ, et al
    Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.
    J Infect Dis. 2018 Jan 18. pii: 4816916. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. CHIU SS, Kwan MYW, Feng S, Wong JSC, et al
    Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17.
    J Infect Dis. 2018 Jan 16. pii: 4810661. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. KAPIL P, Papin JF, Wolf RF, Zimmerman LI, et al
    Maternal Vaccination with a Mono-component Pertussis Toxoid Vaccine is Sufficient to Protect Infants in a Baboon Model of Whooping Cough.
    J Infect Dis. 2018 Jan 15. pii: 4808590. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. CAPEDING MR, Alberto ER, Bouckenooghe A, Laot TM, et al
    Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    J Infect Dis. 2018 Jan 9. pii: 4794746. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. PRINGLE KD, Burke RM, Steiner CA, Parashar UD, et al
    Trends in Rate of Seizure-Associated Hospitalizations Among Children <5 Years Old Before and After Rotavirus Vaccine Introduction in the United Sates, 2000-2013.
    J Infect Dis. 2018 Jan 9. pii: 4796788. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. FONG Y, Shen X, Ashley VC, Deal A, et al
    Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505.
    J Infect Dis. 2018 Jan 8. pii: 4792964. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. BRICKLEY EB, Strauch CB, Wieland-Alter WF, Connor RI, et al
    Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
    J Infect Dis. 2018 Jan 3. pii: 4788281. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. SUTTER RW
    Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine.
    J Infect Dis. 2018 Jan 3. pii: 4788256. doi: 10.1093.
    PubMed     Text format    


  64. GIRI S, Kumar N, Dhanapal P, Venkatesan J, et al
    The quantity of vaccine poliovirus shedding determines the titer of the serum neutralizing antibody response in Indian children vaccinated with oral vaccine.
    J Infect Dis. 2018 Jan 2. pii: 4782493. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  65. RAMILO O, Rodriguez-Fernandez R, Mejias A
    One Step Forward in the Road Toward a Universal Influenza Vaccine.
    J Infect Dis. 2017;217:1-2.
    PubMed     Text format    


  66. MAJUMDAR M, Klapsa D, Wilton T, Akello J, et al
    Isolation of vaccine-like poliovirus strains in sewage samples from the UK.
    J Infect Dis. 2017 Dec 22. pii: 4772162. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. MEYER M, Huang E, Yuzhakov O, Ramanathan P, et al
    Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.
    J Infect Dis. 2017 Dec 21. pii: 4770157. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. DURBIN AP, Whitehead SS
    Zika Vaccines: Role for Controlled Human Infection.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  69. MORABITO KM, Graham BS
    Zika Virus Vaccine Development.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  70. GRUBER MF, Farizo KM, Pratt RD, Fink DL, et al
    Clinical Development Strategies and Considerations for Zika Vaccine Licensure.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  71. VOIGT EA, Haralambieva IH, Larrabee BL, Kennedy RB, et al
    Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination.
    J Infect Dis. 2017 Dec 14. pii: 4743250. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. MADARAS-KELLY K, Remington R, Hruza H, Xu D, et al
    The Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines in Preventing Post-Influenza Deaths.
    J Infect Dis. 2017 Dec 9. pii: 4718125. doi: 10.1093.
    PubMed     Text format    


  73. YOUNG B, Sadarangani S, Jiang L, Wilder-Smith A, et al
    The Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis and Meta-regression of Test-Negative Design Case-control Studies.
    J Infect Dis. 2017 Dec 6. pii: 4694421. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. OHFUJI S, Deguchi M, Tachibana D, Koyama M, et al
    Protective effect of maternal influenza vaccination on influenza in their infants: a prospective cohort study.
    J Infect Dis. 2017 Dec 5. pii: 4693945. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. BURN C, Ramsey N, Garforth SJ, Almo S, et al
    An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, DeltagD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2.
    J Infect Dis. 2017 Dec 5. pii: 4693944. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. LIU WC, Lin CS, Yeh CC, Wu HY, et al
    Effect of Influenza Vaccination Against Postoperative Pneumonia and Mortality for Geriatric Patients Receiving Major Surgery: A Nationwide Matched Study.
    J Infect Dis. 2017 Dec 5. pii: 4690590. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. HAGAN JE, Takashima Y, Sarankhuu A, Dashpagma O, et al
    Risk Factors for Measles Virus Infection Among Adults During a Large Outbreak in Postelimination Era in Mongolia, 2015.
    J Infect Dis. 2017;216:1187-1195.
    PubMed     Text format     Abstract available


    November 2017
  78. MOODIE Z, Juraska M, Huang Y, Zhuang Y, et al
    Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
    J Infect Dis. 2017 Nov 29. pii: 4675250. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. SCHERER EM, Smith RA, Carter JJ, Wipf GC, et al
    Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine.
    J Infect Dis. 2017 Nov 24. pii: 4657105. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. HIRAMATSU H, Suzuki R, Nagatani A, Boda H, et al
    Rotavirus vaccination can be performed without viral dissemination in the Neonatal Intensive Care Unit.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. DREW DR, Sanders PR, Weiss G, Gilson PR, et al
    Functional conservation of the AMA1 host-cell invasion ligand between P. falciparum and P. vivax: a novel platform to accelerate vaccine and drug development.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. CHEN HL, Wen WH, Chang MH
    Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  83. OLDFIELD NJ, Green LR, Parkhill J, Bayliss CD, et al
    Limited impact of adolescent meningococcal ACWY vaccination on group W carriage in university students.
    J Infect Dis. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  84. LEROUX-ROELS G, Cramer JP, Mendelman PM, Sherwood J, et al
    Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  85. WOESTENBERG PJ, King AJ, van Benthem BHB, Donken R, et al
    Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors.
    J Infect Dis. 2017 Nov 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. NOVAKOVIC D, Cheng ATL, Zurynski Y, Booy R, et al
    A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program.
    J Infect Dis. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. DONOVAN B, Callander D
    Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue.
    J Infect Dis. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format    


  88. SALEEM AF, Mach O, Yousafzai MT, Khan A, et al
    Immunogenicity of Different Routine Poliovirus Vaccination Schedules: a Randomized Controlled Trial, Karachi, Pakistan.
    J Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. VANDERVEN HA, Jegaskanda S, Wines BD, Hogarth PM, et al
    Antibody-dependent cellular cytotoxicity (ADCC) responses to seasonal influenza vaccination in older adults.
    J Infect Dis. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  90. SICRE DE FONTBRUNE F, Arnaud C, Cheminant M, Boulay A, et al
    Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy.
    J Infect Dis. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. SKOWRONSKI DM, Chambers C, De Serres G
    Selection bias in the assessment of frailty and its role in influenza vaccine effectiveness evaluation among elderly adults.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format    


  92. SKOWRONSKI DM, Chambers C, Sabaiduc S, De Serres G, et al
    Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-16 season in Canada.
    J Infect Dis. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  93. BELONGIA E
    Beyond Antigenic Match: Moving Toward Greater Understanding of Influenza Vaccine Effectiveness.
    J Infect Dis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format    


  94. OXMAN MN, Harbecke R, Koelle DM
    Clinical Usage of the Candidate Adjuvanted HZ/su Zoster Vaccine: re-vaccination of recipients of live attenuated zoster vaccine and co-administration with a seasonal influenza vaccine.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    


  95. SCHWARZ TF, Aggarwal N, Moeckesch B, Schenkenberger I, et al
    Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. GRUPPING K, Campora L, Douha M, Heineman TC, et al
    Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. FALLOON J, Yu J, Esser MT, Villafana T, et al
    An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. NICHOLSON E, Piedra PA
    Local Versus Global Enterovirus (EV) Surveillance: A Discussion For The Need for Active Surveillance To Guide EV A71 Vaccines.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  99. LANGLEY JM
    Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  100. LEVINE MZ, Holiday C, Liu F, Jefferson S, et al
    Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  101. JONES EN, Amoah S, Cao W, Sambhara S, et al
    An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  102. PODDIGHE D
    2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine.
    J Infect Dis. 2017;216:782-783.
    PubMed     Text format    


  103. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


  104. TORRESI J, Richmond PC, Heron LG, Qiao M, et al
    Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. DROLET M, Laprise JF, Brotherton JML, Donovan B, et al
    The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation.
    J Infect Dis. 2017 Sep 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. DUNKLE LM, Izikson R, Patriarca PA, Goldenthal KL, et al
    Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    J Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. AKE JA, Schuetz A, Pegu P, Wieczorek L, et al
    Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. NING T, Wolfe A, Nie J, Huang W, et al
    Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. OLIVER SE, Unger ER, Lewis R, McDaniel D, et al
    Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    J Infect Dis. 2017;216:594-603.
    PubMed     Text format     Abstract available


    August 2017
  110. MCNAMARA LA, Thomas JD, MacNeil J, Chang HY, et al
    Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp - Oregon, 2015-2016.
    J Infect Dis. 2017 Aug 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  111. LEHTINEN T, Soderlund-Strand A, Petaja T, Eriksson T, et al
    Human papillomavirus (HPV) prevalence in adolescent males four years post HPV16/18 vaccination.
    J Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  112. MODROF J, Tille B, Farcet MR, McVey J, et al
    Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins:is an Increase by Re-Vaccination of Plasma Donors possible?
    J Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  113. NEUZIL KM, Chen WH
    Influenza Vaccines for Older Persons: Progress and Pitfalls.
    J Infect Dis. 2017;216:397-398.
    PubMed     Text format    


  114. ANDREW MK, Shinde V, Ye L, Hatchette T, et al
    The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
    J Infect Dis. 2017;216:405-414.
    PubMed     Text format     Abstract available


  115. VAN BEEK J, Veenhoven RH, Bruin JP, van Boxtel RAJ, et al
    Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections.
    J Infect Dis. 2017;216:415-424.
    PubMed     Text format     Abstract available


  116. MCELHANEY JE, McNeil SA
    Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults.
    J Infect Dis. 2017;216:399-401.
    PubMed     Text format    


  117. LIBRATY DH
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017;216:502-503.
    PubMed     Text format    


  118. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


  119. BAUSSANO I, Lazzarato F, Ronco G, Lehtinen M, et al
    Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
    J Infect Dis. 2017;216:336-344.
    PubMed     Text format     Abstract available


  120. MOHAN VR, Karthikeyan R, Babji S, McGrath M, et al
    Rotavirus Infection and Disease in a Multisite Birth Cohort: Results From the MAL-ED Study.
    J Infect Dis. 2017;216:305-316.
    PubMed     Text format     Abstract available


    July 2017
  121. VERSCHOOR CP, Lelic A, Parsons R, Evelegh C, et al
    Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.
    J Infect Dis. 2017;216:191-197.
    PubMed     Text format     Abstract available


  122. OPERARIO DJ, Platts-Mills JA, Nadan S, Page N, et al
    Etiology of Severe Acute Watery Diarrhea in Children in the Global Rotavirus Surveillance Network Using Quantitative Polymerase Chain Reaction.
    J Infect Dis. 2017;216:220-227.
    PubMed     Text format     Abstract available


  123. HOLMES M, Abimbola T, Lusiana M, Pallas S, et al
    Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  124. ZIPURSKY S, Patel M, Farrell M, Gonzalez AR, et al
    Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  125. NNADI C, Etsano A, Uba B, Ohuabunwo C, et al
    Approaches to Vaccination Among Populations in Areas of Conflict.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  126. WALLACE AS, Bohara R, Stewart S, Subedi G, et al
    Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  127. FAHMY K, Hampton LM, Langar H, Patel M, et al
    Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  128. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  129. BURNETT E, Wannemuehler K, Ngoie Mwamba G, Yolande M, et al
    Individually Linked Household and Health Facility Vaccination Survey in 12 At-risk Districts in Kinshasa Province, Democratic Republic of Congo: Methods and Metadata.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  130. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  131. HAMPTON LM, du Chatellier GM, Fournier-Caruana J, Ottosen A, et al
    Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  132. DIOP OM, Kew OM, de Gourville EM, Pallansch MA, et al
    The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  133. MULDERS MN, Serhan F, Goodson JL, Icenogle J, et al
    Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  134. MENNING L, Garg G, Pokharel D, Thrush E, et al
    Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  135. DOLAN SB, Patel M, Hampton LM, Burnett E, et al
    Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  136. OSADEBE LU, MacNeil A, Elmousaad H, Davis L, et al
    Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April-November 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  137. OKAYASU H, Sein C, Chang Blanc D, Gonzalez AR, et al
    Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  138. RAMIREZ GONZALEZ A, Farrell M, Menning L, Garon J, et al
    Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  139. TEVI-BENISSAN C, Okeibunor J, du Chatellier GM, Assefa A, et al
    Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  140. BAHL S, Hasman A, Eltayeb AO, James Noble D, et al
    The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  141. BA-NGUZ A, Adjagba A, Wisnu Hendrarto T, Sewankambo NK, et al
    The Role of National Immunization Technical Advisory Groups (NITAGs) in the Introduction of Inactivated Polio Vaccine: Experience of the Indonesia and Uganda NITAGs.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  142. WASSILAK SGF, Williams CL, Murrill CS, Dahl BA, et al
    Using Acute Flaccid Paralysis Surveillance as a Platform for Vaccine-Preventable Disease Surveillance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  143. BILLAH MM, Zaman K, Estivariz CF, Snider CJ, et al
    Cold-Chain Adaptability During Introduction of Inactivated Polio Vaccine in Bangladesh, 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  144. SHENDALE S, Farrell M, Hampton LM, Harris JB, et al
    Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  145. GURUNG S, Harris JB, Eltayeb AO, Hampton LM, et al
    Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  146. BLANKENHORN AL, Cernuschi T, Zaffran MJ
    Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  147. WANYOIKE S, Ramirez Gonzalez A, Dolan SB, Garon J, et al
    Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  148. RUBIN J, Ottosen A, Ghazieh A, Fournier-Caruana J, et al
    Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  149. PREZA I, Subaiya S, Harris JB, Ehlman DC, et al
    Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  150. DECINA D, Fournier-Caruana J, Takane M, Ostad Ali Dehaghi R, et al
    Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  151. LEWIS I, Ottosen A, Rubin J, Blanc DC, et al
    A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  152. SCOTNEY S, Snidal S, Saidu Y, Ojumu A, et al
    Succeeding in New Vaccine Introduction: Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Cameroon, Kenya, and Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  153. ONGWAE KM, Bawa SB, Shuaib F, Braka F, et al
    Use of Dedicated Mobile Teams and Polio Volunteer Community Mobilizers to Increase Access to Zero-Dose Oral Poliovirus Vaccine and Routine Childhood Immunizations in Settlements at High Risk for Polio Transmission in Northern Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  154. ESTIVARIZ CF, Snider CJ, Anand A, Hampton LM, et al
    Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  155. FARRELL M, Hampton LM, Shendale S, Menning L, et al
    Monitoring and Validation of the Global Replacement of tOPV with bOPV, April-May 2016.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  156. GUIRGUIS S, Obregon R, Coleman M, Hickler B, et al
    Placing Human Behavior at the Center of the Fight to Eradicate Polio: Lessons Learned and Their Application to Other Life-Saving Interventions.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  157. PATEL M, Cochi S
    Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  158. ZIPURSKY S, Vandelaer J, Brooks A, Dietz V, et al
    Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  159. PEDREIRA C, Thrush E, Jauregui B
    Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    June 2017
  160. LAVERDE D, Probst I, Romero-Saavedra F, Kropec A, et al
    Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.
    J Infect Dis. 2017;215:1836-1845.
    PubMed     Text format     Abstract available


  161. MAERTENS K, Tran TMP, Hens N, Van Damme P, et al
    Effect of Prepregnancy Pertussis Vaccination in Young Infants.
    J Infect Dis. 2017;215:1855-1861.
    PubMed     Text format     Abstract available


  162. MONTO AS, Malosh RE, Petrie JG, Martin ET, et al
    The Doctrine of Original Antigenic Sin: Separating Good From Evil.
    J Infect Dis. 2017;215:1782-1788.
    PubMed     Text format     Abstract available


  163. CHUNG JR, Flannery B, Zimmerman RK, Nowalk MP, et al
    Prior season vaccination and risk of influenza during the 2014-2015 season in the U.S.
    J Infect Dis. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


  164. HUANG LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, et al
    Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
    J Infect Dis. 2017 Jun 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  165. QENDRI V, Bogaards JA, Berkhof J
    Health and economic impact of a tender-based gender-neutral HPV16/18 vaccination program in the Netherlands.
    J Infect Dis. 2017 Jun 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  166. HALPERIN SA, Arribas JR, Rupp R, Andrews CP, et al
    Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
    J Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  167. FLECKENSTEIN JM
    Providing Structure to Enterotoxigenic Escherichia coli Vaccine Development.
    J Infect Dis. 2017 May 24. doi: 10.1093.
    PubMed     Text format    


  168. LOCHT C, Papin JF, Lecher S, Debrie AS, et al
    Live attenuated pertussis vaccine BPZE1 protects baboons against B. pertussis disease and infection.
    J Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  169. YAO Y, Lai R, Afkhami S, Haddadi S, et al
    A novel virus-vectored respiratory mucosal vaccine enhances anti-tuberculosis immunity in a humanized model system.
    J Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  170. SCHNELL MJ
    Editorial to: 6-Month Safety Data of Ebola Zaire Vaccine (rVSVDeltaG-ZEBOV-GP) in a Phase III Double Blind, Placebo Controlled Randomized Study in Healthy Adults.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


  171. S NELSON EA, Steele AD
    Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality from Diarrhea.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


  172. BURNETT E, Jonesteller CL, Tate JE, Yen C, et al
    Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality from Diarrhea.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  173. RERKS-NGARM S, Pitisuttithum P, Excler JL, Nitayaphan S, et al
    Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    J Infect Dis. 2017;215:1255-1263.
    PubMed     Text format     Abstract available


  174. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  175. MOHN KG, Zhou F, Brokstad KA, Sridhar S, et al
    Live attenuated influenza vaccination boosts durable cross-reactive and protection-associated T-cells in children.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  176. BUCKWALTER CM, Currie EG, Tsang RS, Gray-Owen SD, et al
    Licensed meningococcal serogroup B vaccine-induced immunity against invasive disease does not reflect protection against nasal colonization in a humanized mouse model.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  177. FLANAGAN KL
    Measles Vaccination Is Effective at Under Nine Months of Age, and Provides Nonspecific Immunological Benefits.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  178. WOUDENBERG T, van der Maas NA, Knol MJ, de Melker H, et al
    Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  179. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017;215:841-843.
    PubMed     Text format    


  180. MARTINEZ-BAZ I, Casado I, Navascues A, Diaz-Gonzalez J, et al
    Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus.
    J Infect Dis. 2017;215:847-855.
    PubMed     Text format     Abstract available


  181. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017;215:928-932.
    PubMed     Text format     Abstract available


  182. LINDESMITH LC, Mallory ML, Jones TA, Richardson C, et al
    Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    J Infect Dis. 2017;215:984-991.
    PubMed     Text format     Abstract available


  183. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
    J Infect Dis. 2017;215:844-846.
    PubMed     Text format    


  184. SINGH P, Verma D, Backstedt BT, Kaur S, et al
    Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.
    J Infect Dis. 2017;215:1000-1009.
    PubMed     Text format     Abstract available


  185. SHAY DK, Chillarige Y, Kelman J, Forshee RA, et al
    Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.
    J Infect Dis. 2017 Mar 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  186. MONTO AS
    Moving Toward Improved Influenza Vaccines.
    J Infect Dis. 2017 Mar 2. doi: 10.1093.
    PubMed     Text format    


    February 2017
  187. KARAUZUM H, Haudenschild CC, Moore IN, Mahmoudieh M, et al
    Vaccination induces CD4 T cell-mediated mortality during Staphylococcus aureus bacteremia.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  188. JANES HE, Cohen KW, Frahm N, De Rosa SC, et al
    Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  189. SKOWRONSKI DM, Chambers C, De Serres G, Sabaiduc S, et al
    Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15.
    J Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    



  190. Flu vaccine - too much of a good thing?
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  191. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  192. MARTINEZ-BAZ I, Casado I, Navascues A, Diaz-Gonzalez J, et al
    Effect of Repeated Vaccination With the Same Vaccine Component Against Influenza A(H1N1)pdm09.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  193. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  194. LINDESMITH LC, Mallory ML, Jones TA, Richardson C, et al
    Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    J Infect Dis. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


    January 2017
  195. BERNSTEIN DI, Wald A, Warren T, Fife K, et al
    Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings from a Randomized Trial.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. CLARK S, Lanni F, Marinova D, Rayner E, et al
    Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    J Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  197. KAZI AM, Cortese MM, Yu Y, Lopman B, et al
    Secretor and salivary ABO blood group antigen status predict rotavirus vaccine-take in infants.
    J Infect Dis. 2017 Jan 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  198. FEROLDI E, Boaz M, Yoksan S, Chokephaibulkit K, et al
    Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
    J Infect Dis. 2017;215:221-227.
    PubMed     Text format     Abstract available


  199. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus 2.
    J Infect Dis. 2017 Jan 11. pii: jix006. doi: 10.1093.
    PubMed     Text format    


  200. DO VA, Biering-Sorensen S, Fisker AB, Bale C, et al
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017 Jan 10. pii: jiw512. doi: 10.1093.
    PubMed     Text format     Abstract available


  201. RESIK S, Tejeda A, Diaz M, Okayasu H, et al
    Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    J Infect Dis. 2017 Jan 9. pii: jiw492. doi: 10.1093.
    PubMed     Text format     Abstract available


  202. NYOMBAYIRE J, Anzala O, Gazzard B, Karita E, et al
    First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    J Infect Dis. 2017;215:95-104.
    PubMed     Text format     Abstract available


  203. WEI M, Meng F, Wang S, Li J, et al
    2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
    J Infect Dis. 2017;215:56-63.
    PubMed     Text format     Abstract available


  204. PIERCE KK, Whitehead SS, Kirkpatrick BD, Grier PL, et al
    A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Delta30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
    J Infect Dis. 2017;215:52-55.
    PubMed     Text format     Abstract available


  205. HEIKKINEN T, Ojala E, Waris M
    Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children.
    J Infect Dis. 2017;215:17-23.
    PubMed     Text format     Abstract available


    December 2016
  206. HADLER JL
    Christmas-New Year influenza lull: not too late for vaccination.
    J Infect Dis. 2016 Dec 28. pii: jiw643. doi: 10.1093.
    PubMed     Text format    


  207. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  208. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  209. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  210. DONKEN R, Schurink-van 't Klooster TM, Schepp RM, van der Klis FR, et al
    Immune responses after two- versus three-doses of HPV vaccination up to 4(1/2) years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D).
    J Infect Dis. 2016 Dec 23. pii: jiw588. doi: 10.1093.
    PubMed     Text format     Abstract available


  211. MOSLEY YC, Radder JE, Berndt A, HogenEsch H, et al
    Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice.
    J Infect Dis. 2016 Dec 23. pii: jiw587. doi: 10.1093.
    PubMed     Text format     Abstract available


  212. HEARD I, Tondeur L, Arowas L, Demazoin M, et al
    Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France.
    J Infect Dis. 2016 Dec 23. pii: jiw639. doi: 10.1093.
    PubMed     Text format     Abstract available


  213. WANG X, Fan X, Bi S, Li N, et al
    Toll-like Receptor 2-and 4-Mediated Reciprocal Th17 and Antibody Responses to Group A Streptococcus Infection.
    J Infect Dis. 2016 Dec 23. pii: jiw598. doi: 10.1093.
    PubMed     Text format     Abstract available


  214. JEGASKANDA S, Co MD, Cruz J, Subbarao K, et al
    Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein.
    J Infect Dis. 2016 Dec 23. pii: jiw629. doi: 10.1093.
    PubMed     Text format     Abstract available


  215. TRIEU MC, Zhou F, Lartey S, Jul-Larsen A, et al
    Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination.
    J Infect Dis. 2016 Dec 22. pii: jiw619. doi: 10.1093.
    PubMed     Text format     Abstract available


  216. JOHN J, Giri S, Karthikeyan AS, Lata D, et al
    The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomised controlled trial.
    J Infect Dis. 2016 Dec 21. pii: jiw595. doi: 10.1093.
    PubMed     Text format     Abstract available


  217. PETRIE JG, Parkhouse K, Ohmit SE, Malosh RE, et al
    Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.
    J Infect Dis. 2016;214:1947-1951.
    PubMed     Text format     Abstract available


  218. RAMSAUER K, Tangy F
    Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  219. DEZURE AD, Berkowitz NM, Graham BS, Ledgerwood JE, et al
    Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  220. ERASMUS JH, Rossi SL, Weaver SC
    Development of Vaccines for Chikungunya Fever.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  221. HENEIN S, Swanstrom J, Byers AM, Moser JM, et al
    Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue exposed individuals.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  222. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016.
    PubMed     Text format    


  223. COLLETT MS, Hincks JR, Benschop K, Duizer E, et al
    Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  224. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016 Dec 7. doi: 10.1093.
    PubMed     Text format    


    November 2016
  225. BERENSON AB, Laz TH, Rahman M
    Reduction in vaccine-type human papillomavirus prevalence among adult females in the United States, 2009-2012.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  226. ABEID KA, Jani B, Cortese MM, Kamugisha C, et al
    Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data from the First 3 Years Post-Introduction.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  227. MACHALEK DA, Chow EP, Garland SM, Wigan R, et al
    Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    October 2016
  228. WU Y, Chakravarty S, Li M, Wai TT, et al
    Development of a live attenuated bivalent oral vaccine against Shigella sonnei shigellosis and typhoid fever.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  229. HARRIS VC, Armah G, Fuentes S, Korpela KE, et al
    The infant gut microbiome correlates significantly with rotavirus vaccine response in rural Ghana.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  230. ITURRIZA-GOMARA M, Cunliffe NA
    Could the gut microbiome be key to understanding and improving rotavirus vaccine performance in high disease burden settings?
    J Infect Dis. 2016.
    PubMed     Text format    


  231. SCHLECHT NF, Diaz A, Shankar V, Szporn AH, et al
    RISK OF DELAYED HPV VACCINATION IN INNER-CITY ADOLESCENT WOMEN.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  232. MORI I
    Vaccination Effectively Prevents Central Nervous System Invasion by Influenza A(H5N1) Virus Through the Olfactory Pathway: A Proposed Mechanism of Neuroprotection.
    J Infect Dis. 2016.
    PubMed     Text format    


  233. LELIC A, Verschoor CP, Lau VW, Parsons R, et al
    Immunogenicity of Varicella Zoster Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  234. JEYANATHAN M, Damjanovic D, Yao Y, Bramson J, et al
    Induction of an immune protective T cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in man.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  235. XIONG X, Jiao J, Gregory AE, Wang P, et al
    Identification of Coxiella burnetii CD8+ epitopes and delivery by attenuated Listeria monocytogenes as a vaccine vector in a C57BL/6 mouse model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  236. Live attenuated influenza vaccine in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format    


    September 2016
  237. ENGLUND JA, Chu HY
    Vaccines Against Respiratory Syncytial Virus: The Time Has Come.
    J Infect Dis. 2016.
    PubMed     Text format    


  238. LANGLEY JM, Aggarwal N, Toma A, Halperin SA, et al
    A randomized, controlled, observer-blind Phase I study of the safety and immunogenicity of a Respiratory Syncytial Virus vaccine with or without alum adjuvant.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  239. HALSTEAD SB
    Dengue Vaccine Efficacy: Not a Zero Sum Game.
    J Infect Dis. 2016.
    PubMed     Text format    


  240. LIAO G, Li R, Li C, Sun M, et al
    Phase III Trial of a Sabin Strain-based Inactivated Poliovirus Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  241. GOO L, Dowd KA, Lin TY, Mascola JR, et al
    A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  242. MADAN A, Segall N, Ferguson M, Frenette L, et al
    Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  243. MAYORGA O, Buhler S, Jaeger VK, Bally S, et al
    Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  244. SINGH DK, Dwivedi VP, Ranganathan A, Bishai WR, et al
    Blockade of the Kv1.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  245. REBER AJ, Kim JH, Coleman LA, Spencer SM, et al
    Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity with Past and Future Strains.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  246. EDWARDS KM, Keitel WA
    Challenges Remain for Influenza Vaccination of Children.
    J Infect Dis. 2016.
    PubMed     Text format    


  247. KIM JH, Mishina M, Chung JR, Cole KS, et al
    Cell-mediated immunity against antigenically drifted influenza A(H3N2) viruses in children during a vaccine mismatch season.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  248. LEWNARD JA, Huppert A, Givon-Lavi N, Pettigrew MM, et al
    Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory co-colonization with nontypeable Haemophilus influenzae.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  249. SIEGERS JY, van den Brand JM, Leijten LM, van de Bildt MM, et al
    Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
    J Infect Dis. 2016;214:516-24.
    PubMed     Text format     Abstract available


  250. ADLER SP, Manganello AM, Lee R, McVoy MA, et al
    A Phase 1 Study of Four Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in CMV Seronegative Men.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  251. PINTO LA, Kemp TJ, Torres BN, Isaacs K, et al
    THE QUADRIVALENT HPV VACCINE INDUCES HPV-SPECIFIC ANTIBODIES AT THE ORAL CAVITY: RESULTS FROM THE MID-ADULT MALE VACCINE TRIAL-THE MAM TRIAL.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  252. WILDER-SMITH A, Vannice KS, Hombach J, Farrar J, et al
    Population perspectives and WHO recommendations for CYD-TDV dengue vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  253. HALSTEAD S
    Critique of WHO Approval of a Dengue Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  254. WU S, Kroeker A, Wong G, He S, et al
    An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  255. A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  256. MCLEAN HQ, Chow BD, VanWormer JJ, King JP, et al
    The Effect of Statin Use on Influenza Vaccine Effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  257. SHAFER WM
    Does the cervicovaginal microbiome facilitate transmission of Neisseria gonorrhoeae from women to men? Implications for understanding transmission of gonorrhea and advancing vaccine development.
    J Infect Dis. 2016.
    PubMed     Text format    


  258. JOHNSON RF, Kurup D, Hagen KR, Fisher C, et al
    An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  259. HOFT DF, Lottenbach K, Goll JB, Hill H, et al
    Priming Vaccination with H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  260. OLIVERA-BOTELLO G, Coudeville L, Fanouillere K, Guy B, et al
    Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016

  261. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    J Infect Dis. 2016.
    PubMed     Text format    


  262. ATMAR RL, Baehner F, Cramer JP, Song E, et al
    Rapid Responses to Two Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  263. JEGASKANDA S, Luke C, Hickman HD, Sangster MY, et al
    The generation and protective ability of influenza-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection or experimental challenge.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  264. MATTHIJSSE SM, Hontelez JA, Naber SK, Rozemeijer K, et al
    Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  265. RAMPLING T, Ewer KJ, Bowyer G, Bliss CM, et al
    Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  266. BOWEN MD, Mijatovic-Rustempasic S, Esona MD, Teel EN, et al
    Rotavirus Strain Trends during the Post-Licensure Vaccine Era: United States, 2008-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  267. REGULES JA, Cicatelli SB, Bennett JW, Paolino KM, et al
    Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria infection and immunogenicity study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  268. MEITES E, Gorbach PM, Gratzer B, Panicker G, et al
    Monitoring for HPV Vaccine Impact among Gay, Bisexual and other Men who have Sex with Men - United States, 2012-2014.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  269. TOTA JE, Ramanakumar AV, Villa LL, Richardson H, et al
    Cervical Infection with Vaccine Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  270. MOHN KG, Brokstad KA, Pathirana RD, Bredholt G, et al
    Live attenuated influenza vaccination in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  271. SCRIBA TJ, Kaufmann SH, Lambert PH, Sanicas M, et al
    Vaccination against tuberculosis with whole cell mycobacterial vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  272. DE ST MAURICE A, Schaffner W, Griffin MR, Halasa N, et al
    Persistent gender disparities in invasive pneumococcal diseases in the conjugate vaccine era.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  273. LAPRISE JF, Markowitz LE, Chesson HW, Drolet M, et al
    COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  274. PRELOG M, Gorth P, Zwazl I, Kleines M, et al
    Universal mass vaccination against Rotavirus: indirect effects on Rotavirus infections in neonates and non-vaccinated small infants not eligible for vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  275. FLANNERY B, Zimmerman RK, Gubareva LV, Garten RJ, et al
    Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  276. VIROJANAPIROM P, Lumlertdacha B, Wipattanakitchareon A, Hemachudha T, et al
    T-705 as a potential therapeutic in rabies.
    J Infect Dis. 2016.
    PubMed     Text format    


  277. ALI D, Banda R, Mohammed A, Adagadzu J, et al
    Strengthening Routine Immunization in Areas of Northern Nigeria at High Risk for Polio Transmission During 2012-2014.
    J Infect Dis. 2016;213 Suppl 3:S147-50.
    PubMed     Text format     Abstract available


  278. GALI E, Mkanda P, Banda R, Korir C, et al
    Revised Household-Based Microplanning in Polio Supplemental Immunization Activities in Kano State, Nigeria. 2013-2014.
    J Infect Dis. 2016;213 Suppl 3:S73-8.
    PubMed     Text format     Abstract available


  279. JOHNSON MULUH T, Hamisu AW, Craig K, Mkanda P, et al
    Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012-2015.
    J Infect Dis. 2016;213 Suppl 3:S131-5.
    PubMed     Text format     Abstract available


  280. CRAIG KT, Verma H, Iliyasu Z, Mkanda P, et al
    Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014.
    J Infect Dis. 2016;213 Suppl 3:S124-30.
    PubMed     Text format     Abstract available


  281. MUSA A, Mkanda P, Manneh F, Korir C, et al
    Youth Group Engagement in Noncompliant Communities During Supplemental Immunization Activities in Kaduna, Nigeria, in 2014.
    J Infect Dis. 2016;213 Suppl 3:S91-5.
    PubMed     Text format     Abstract available


    April 2016
  282. PRADOS-ROSALES R, Carreno LJ, Weinrick B, Batista-Gonzalez A, et al
    The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  283. MINHINNICK A, Harris S, Wilkie M, Peter J, et al
    Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    J Infect Dis. 2016;213:824-30.
    PubMed     Text format     Abstract available


    February 2016
  284. MASCITELLI L, Goldstein MR
    How regulatory T cells induction by statin drugs may impair influenza vaccine immunogenicity and effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format    


  285. TITA AT, Andrews WW
    Influenza Vaccination and Antiviral Therapy in Pregnant Women.
    J Infect Dis. 2016.
    PubMed     Text format    


    January 2016
  286. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


    October 2015
  287. JONES T
    Comment on Ly and Klevens, Trends in Disease and Complications of Hepatitis A Virus Infection.
    J Infect Dis. 2015.
    PubMed     Text format    


    September 2015
  288. CLIFF JM, Cho JE, Lee JS, Ronacher K, et al
    Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: